Treatment with CXCR4 antagonists or PLC inhibitors improves the survival rate of dexamethasone (Dex)-treated NSG mice, indicating that the targeted inhibition of the CXCR4/PLC axis can significantly reverse the malignant proliferation of B-ALL cells and Dex resistance in ALL [109]. Here, CXCR4 is linked to acute lymphoblastic leukemia.